^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    everolimus

    i
    Other names: RAD, RAD001, SDZ RAD, RAD 001, RAD-001
    Company:
    Generic mfg.
    Drug class:
    mTOR inhibitor
    Related drugs:
    5d
    XPO1 inhibitor KPT-330 disrupts the core transcriptional regulatory circuitry of dedifferentiated liposarcoma by modulating the translation process. (PubMed, Oncogene)
    Furthermore, we identify a synergistic antitumor effect between KPT-330 and translation inhibitors, including everolimus and homoharringtonine. Notably, the disruptive impact of KPT-330 on CRC homeostasis extends to other cancer cell lineages, underscoring its broad mechanistic relevance. Collectively, our findings elucidate a novel mechanism through which KPT-330 destabilizes CRC via translational dysregulation and highlight its potential therapeutic utility in combination regimens for DDLPS.
    Journal
    |
    XPO1 (Exportin 1)
    |
    everolimus • Xpovio (selinexor) • Synribo (omacetaxine mepesuccinate)
    6d
    A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. (clinicaltrials.gov)
    P3, N=400, Recruiting, Pfizer
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    everolimus • fulvestrant • exemestane • prifetrastat (PF-07248144)
    7d
    MONTBLANC: Efficacy and Safety of Everolimus Versus Mycophenolate Mofetil in Liver Transplant Recipients. (clinicaltrials.gov)
    P4, N=150, Completed, Chong Kun Dang Pharmaceutical | Recruiting --> Completed
    Trial completion
    |
    everolimus
    7d
    Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial (clinicaltrials.gov)
    P2, N=100, Recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Apr 2029 | Trial primary completion date: Apr 2026 --> Apr 2029
    Trial completion date • Trial primary completion date
    |
    sunitinib • everolimus • Cabometyx (cabozantinib tablet) • Lutathera (lutetium Lu 177 dotatate)
    7d
    Renal malignant perivascular epithelioid cell tumor: a case report and literature review. (PubMed, Front Oncol)
    Based on the suspected enhancing mass identified at the one-month postoperative CT follow-up and the confirmed malignant potential, the patient has been advised to initiate adjuvant mTOR inhibitor therapy (Everolimus)...In young patients with TSC and atypical renal masses, malignant PEComa should be considered in the differential diagnosis. Multidisciplinary evaluation, genetic testing, and awareness of emerging mTOR-targeted therapies are essential for optimal management.
    Journal
    |
    TSC2 (TSC complex subunit 2) • MLANA (Melan-A)
    |
    everolimus
    8d
    Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) (clinicaltrials.gov)
    P1, N=50, Suspended, University of California, San Francisco | Recruiting --> Suspended
    Trial suspension
    |
    Mekinist (trametinib) • everolimus
    9d
    EVOLVE-BDT: Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (clinicaltrials.gov)
    P2, N=700, Recruiting, UNC Lineberger Comprehensive Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    everolimus • capecitabine • Verzenio (abemaciclib)
    9d
    Thymic epithelial tumors: a narrative review of diagnostic and therapeutic advances. (PubMed, Transl Cancer Res)
    Systemic therapy advances include KIT/PIK3CA-targeted agents (imatinib, everolimus) showing modest efficacy, while programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors demonstrate 20-30% response rates in thymic carcinoma but are associated with a >50% risk of severe immune-related adverse events (irAEs). Platinum-based chemotherapy [cisplatin, doxorubicin, cyclophosphamide (CAP) regimen] remains standard for advanced disease...TETs management is evolving rapidly through technological and biological advances. Future progress hinges on: (I) validating artificial intelligence (AI)-driven imaging classifiers; (II) conducting randomized controlled trials (RCTs) comparing surgical approaches; (III) elucidating immunotherapy toxicity mechanisms; and (IV) developing predictive composite biomarkers integrating genomic, immunological, and clinical parameters to enable precision medicine while mitigating fatal toxicities.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    cisplatin • imatinib • everolimus • doxorubicin hydrochloride • cyclophosphamide
    14d
    A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. (clinicaltrials.gov)
    P3, N=400, Recruiting, Pfizer
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    everolimus • fulvestrant • exemestane • prifetrastat (PF-07248144)
    14d
    The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy (clinicaltrials.gov)
    P1, N=5, Recruiting, Xuanwu Hospital, Beijing | Initiation date: Mar 2026 --> Jul 2026
    Trial initiation date
    |
    everolimus
    15d
    RapaLoad: Everolimus and/or Exercise to Prevent Bone Loss in Postmenopausal Women (clinicaltrials.gov)
    P2, N=136, Active, not recruiting, Odense University Hospital | Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Oct 2026 | Trial primary completion date: Jul 2025 --> Mar 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    everolimus
    15d
    LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy (clinicaltrials.gov)
    P1/2, N=12, Completed, Georgetown University | N=44 --> 12 | Active, not recruiting --> Completed
    Trial completion • Enrollment change
    |
    everolimus • Kisqali (ribociclib)